A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin

JAMA Dermatol. 2014 Feb;150(2):210-2. doi: 10.1001/jamadermatol.2013.5741.

Authors

Kristen Corey¹, Deborah Cook², Jessica Bekker², Emiliano Mugnaini³, Julie H Lin⁴

Affiliations

¹ University of Massachusetts Medical School, Worcester.
² Department of Pathology, University of Vermont College of Medicine, Burlington.
³ Division of Hematology/Oncology, University of Vermont College of Medicine, Burlington.
⁴ Division of Dermatology, University of Vermont College of Medicine, Burlington.

PMID: 24352253
DOI: 10.1001/jamadermatol.2013.5741

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Cell Transformation, Neoplastic
Female
Humans
Immunoconjugates / therapeutic use*
Lymphoma, Large-Cell, Anaplastic / drug therapy
Lymphoma, Large-Cell, Anaplastic / pathology
Sezary Syndrome / drug therapy*
Sezary Syndrome / pathology
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome

Substances

Antineoplastic Agents
Immunoconjugates
Brentuximab Vedotin